Type 2 diabetes and gastric sleeve surgery are increasingly discussed together as evidence grows that sleeve gastrectomy can dramatically improve — and in some cases reverse — type 2 diabetes. Beyond reducing stomach capacity, the procedure triggers profound hormonal and metabolic changes that can lower blood glucose within days of surgery, often before significant weight loss occurs. This article explains how gastric sleeve surgery affects type 2 diabetes, who qualifies for the procedure on the NHS, what remission rates to expect, how diabetes medications must be managed, and what long-term follow-up involves.

How gastric sleeve surgery affects type 2 diabetes

Sleeve gastrectomy improves type 2 diabetes by reducing GLP-1 and ghrelin levels, lowering hepatic glucose output, and improving insulin sensitivity — with blood glucose improvements often seen within days of surgery, before significant weight loss occurs.

Gastric sleeve surgery, formally known as sleeve gastrectomy, involves removing approximately 75–80% of the stomach, leaving a narrow, tube-shaped pouch. This dramatically reduces the volume of food a person can consume and triggers a cascade of hormonal and metabolic changes that go well beyond simple calorie restriction.

One of the most significant effects is a rapid alteration in gut hormones, particularly glucagon-like peptide-1 (GLP-1) and ghrelin. GLP-1 is an incretin hormone that stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon release — both of which are beneficial in type 2 diabetes. Improvements in insulin sensitivity are also observed, though these are largely driven by the rapid reduction in caloric intake and subsequent weight loss rather than a direct effect of GLP-1 alone. Ghrelin, often called the 'hunger hormone', is substantially reduced after surgery because the fundus of the stomach (where ghrelin is primarily produced) is removed. Lower ghrelin levels contribute to reduced appetite and improved metabolic regulation.

Other mechanisms under investigation include changes in bile acid signalling, altered nutrient transit, shifts in the gut microbiome, and vagal nerve pathway changes — all of which may contribute to the metabolic benefits observed after surgery.

Importantly, improvements in blood glucose control are often observed within days of surgery — well before significant weight loss has occurred. This early effect is thought to be driven primarily by the sharp reduction in caloric intake, which rapidly decreases hepatic glucose output, alongside the hormonal shifts described above.

For many patients with type 2 diabetes, these combined effects can lead to a significant reduction in HbA1c levels, decreased reliance on diabetes medications, and in some cases, remission of the condition. Understanding these mechanisms helps both patients and clinicians set realistic expectations and plan appropriate post-operative care.

Who is eligible for bariatric surgery on the NHS

NICE criteria support NHS bariatric surgery referral for adults with a BMI of 40 kg/m² or above, or BMI 35–39.9 kg/m² with type 2 diabetes; those with recent-onset type 2 diabetes may be considered from BMI 30 kg/m².

Access to bariatric surgery on the NHS is governed by criteria set out by the National Institute for Health and Care Excellence (NICE). Current NICE obesity guidance identifies several routes through which bariatric surgery may be considered for adults:

• A BMI of 40 kg/m² or above, regardless of the presence of other conditions

• A BMI of 35–39.9 kg/m² with one or more significant obesity-related conditions, such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• A BMI of 30–34.9 kg/m² with recent-onset type 2 diabetes (typically within the last ten years), where evidence suggests a greater likelihood of remission

• People of Asian family origin may be considered at a lower BMI threshold, reflecting higher metabolic risk at lower body weights — the specific threshold is determined by clinical assessment rather than a fixed reduction

These are alternative routes to consideration, not criteria that all must be met simultaneously.

For most patients, surgery is considered when non-surgical weight management options have been tried and found insufficient. However, people with recent-onset type 2 diabetes may be fast-tracked for assessment and do not necessarily need to complete all non-surgical programmes before being referred for surgical evaluation.

Referral is typically made through a GP to a specialist Tier 3 or Tier 4 weight management service, where a multidisciplinary team (MDT) — including a bariatric surgeon, dietitian, psychologist, and physician — will assess suitability. Psychological assessment is a standard part of the pre-operative pathway to ensure patients are prepared for the significant lifestyle changes required. Waiting times vary across NHS trusts, and some patients may be offered surgery through NHS-commissioned independent sector providers. Patients are encouraged to discuss eligibility with their GP or diabetes care team at the earliest opportunity.

Remission rates and long-term blood sugar outcomes

Complete type 2 diabetes remission occurs in approximately 30–60% of patients after sleeve gastrectomy in the short to medium term, with higher rates in those with shorter diabetes duration and lower baseline HbA1c.

The evidence supporting gastric sleeve surgery as a treatment for type 2 diabetes is substantial. Studies consistently demonstrate that a significant proportion of patients achieve partial or complete remission of type 2 diabetes following sleeve gastrectomy.

The 2021 international consensus definition of diabetes remission — endorsed by major diabetes organisations — defines remission as an HbA1c below 48 mmol/mol sustained for at least three months without the use of glucose-lowering medication. Using this definition:

• Complete remission is reported in approximately 30–60% of patients in the short to medium term following sleeve gastrectomy, with rates varying according to the duration of diabetes, baseline HbA1c, degree of weight loss, and how long after surgery outcomes are measured

• Partial remission or significant improvement in glycaemic control is seen in a further proportion of patients who do not achieve full remission

• Patients with shorter duration of diabetes (under five years), lower HbA1c at baseline, and better preserved beta-cell function tend to have the highest remission rates

• It is worth noting that Roux-en-Y gastric bypass is generally associated with higher remission rates than sleeve gastrectomy; this may be a factor in procedure selection for some patients

Long-term outcomes are more variable. Some patients experience a gradual return of diabetes over five to ten years, particularly if significant weight regain occurs. Long-term data from randomised trials such as the SLEEVEPASS study (comparing sleeve gastrectomy with gastric bypass over ten years) and large systematic reviews suggest that bariatric surgery reduces the risk of diabetes-related complications, including cardiovascular events and microvascular disease, even in patients who do not achieve full remission.

It is important that patients understand remission is not guaranteed and that ongoing lifestyle commitment is essential to sustaining metabolic benefits. Regular monitoring of HbA1c and fasting glucose remains necessary throughout the post-operative period, regardless of initial outcomes.

Managing diabetes medications before and after surgery

SGLT-2 inhibitors must be stopped at least three days before surgery; post-operatively, sulphonylureas and insulin carry significant hypoglycaemia risk and must be reduced or stopped promptly under medical supervision.

Careful medication management is a critical component of the peri-operative pathway for patients with type 2 diabetes undergoing gastric sleeve surgery. Failure to adjust medications appropriately can result in dangerous hypoglycaemia or, conversely, inadequate glycaemic control during the recovery period. Patients should follow the specific plan agreed with their diabetes team or GP, in line with current UK peri-operative guidance (including CPOC and JBDS-IP recommendations).

Before surgery, the diabetes care team will typically review and adjust medications:

• SGLT-2 inhibitors (such as dapagliflozin or empagliflozin) should be stopped at least three days before surgery (four days for ertugliflozin) due to the risk of euglycaemic diabetic ketoacidosis (DKA). They should only be restarted once the patient is eating and drinking normally, is clinically stable, and ketone levels have been confirmed as acceptable

• Metformin is generally withheld on the day of surgery and reintroduced cautiously once oral intake is re-established and renal function is confirmed to be stable

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide): peri-operative management should follow local anaesthesia and surgical team policy, as guidance is evolving — particularly regarding aspiration risk. Patients should discuss this with their clinical team before surgery

After surgery, blood glucose levels often fall rapidly, sometimes within the first 24–48 hours. This means that:

• Sulphonylureas (e.g., gliclazide) and insulin carry a significant risk of hypoglycaemia and doses must be reduced or stopped promptly under medical supervision

• Metformin is often reintroduced at a low dose once the patient is tolerating a full liquid or soft diet and renal function is satisfactory

• DPP-4 inhibitors and other agents should be reviewed as part of the agreed post-operative plan

Patients should be provided with clear written guidance on hypoglycaemia recognition and management, including when to seek urgent medical attention. Frequent capillary blood glucose monitoring — or use of a continuous glucose monitor (CGM) where available — is strongly recommended in the early post-operative weeks, with clear thresholds for seeking urgent help (for example, recurrent hypoglycaemia or symptoms suggestive of DKA). Medication changes should always be made in consultation with the diabetes team or GP — patients must not alter doses independently without professional advice.

Risks, complications, and important considerations

Key risks include staple line leak (1–3%), worsening gastro-oesophageal reflux, nutritional deficiencies, and thiamine deficiency if vomiting is prolonged — all requiring lifelong monitoring and specialist follow-up.

Not sure if this is normal? Chat with one of our pharmacists →

Whilst gastric sleeve surgery offers significant metabolic benefits, it is not without risk. Patients and clinicians must weigh these carefully as part of the shared decision-making process, in line with NICE guidance and General Medical Council (GMC) standards for informed consent.

Short-term surgical risks include:

• Staple line leak — a rare but serious complication occurring in approximately 1–3% of cases, requiring urgent intervention

• Bleeding, infection, and venous thromboembolism (VTE) — standard surgical risks mitigated by prophylactic anticoagulation and early mobilisation

• Anaesthetic complications, which may be heightened in patients with obesity-related comorbidities

Longer-term complications specific to sleeve gastrectomy include:

• Gastro-oesophageal reflux disease (GORD) — a well-recognised consequence, as the reduced stomach capacity and altered anatomy can worsen or precipitate reflux symptoms. Patients with pre-existing severe GORD or hiatus hernia should discuss whether sleeve gastrectomy or Roux-en-Y gastric bypass is more appropriate for them, as bypass is generally preferred in this context

• Nutritional deficiencies — particularly vitamin B12, iron, folate, vitamin D, and calcium, requiring lifelong supplementation (see below)

• Gallstones — rapid weight loss increases the risk of gallstone formation; ursodeoxycholic acid may be prescribed in the early post-operative period per local policy

• Weight regain — possible over time if dietary and behavioural changes are not maintained

• Thiamine (vitamin B1) deficiency — patients who experience persistent vomiting after surgery are at risk of thiamine deficiency, which can cause serious neurological complications including Wernicke's encephalopathy. Urgent medical review and thiamine supplementation are required if vomiting is prolonged

NICE guidance emphasises that bariatric surgery should be performed in specialist centres with access to a multidisciplinary team (MDT), including a bariatric surgeon, dietitian, psychologist, and physician. Post-operative nutritional monitoring should follow guidance from the British Obesity and Metabolic Surgery Society (BOMSS). Patients should be fully informed of all risks before proceeding and encouraged to ask questions throughout the consent process.

Safety-netting: patients should seek urgent medical attention if they experience severe abdominal pain, rapid heart rate, or fever (which may indicate a staple line leak), persistent vomiting, signs of DKA, or recurrent hypoglycaemia.

Life after gastric sleeve: diet, monitoring, and follow-up care

Long-term success requires lifelong nutritional supplementation, structured dietary progression, regular blood tests every three to six months initially, and ongoing engagement with the bariatric MDT, GP, and diabetes team.

Long-term success following gastric sleeve surgery depends heavily on sustained lifestyle changes, regular monitoring, and engagement with follow-up care. Surgery is a powerful tool, but it functions best as part of a comprehensive, lifelong approach to health management.

Dietary progression after surgery follows a structured pathway that varies between bariatric centres — patients should always follow the specific plan provided by their own surgical team. A typical example is:

• Weeks 1–2: Clear fluids only

• Weeks 3–4: Full fluids and puréed foods

• Weeks 5–6: Soft, moist foods

• Week 7 onwards: Gradual return to a normal, balanced diet in small portions

Patients are advised to eat slowly, chew thoroughly, avoid drinking fluids with meals, and prioritise protein-rich foods to preserve muscle mass. High-sugar and high-fat foods should be minimised to prevent weight regain and reduce the risk of reactive (post-prandial) hypoglycaemia — a condition where blood sugar drops sharply after eating, which can occur after bariatric surgery. If post-prandial hypoglycaemia is suspected, patients should be referred back to the bariatric MDT and dietitian for structured dietary assessment and management.

Nutritional supplementation is lifelong. Patients should take supplements as directed by their dietitian, in line with BOMSS guidance. A typical UK regimen includes a complete bariatric multivitamin–mineral supplement, vitamin D, calcium (in a form and dose advised by the dietitian), and vitamin B12 — often given as intramuscular injections in the UK. Iron supplementation is recommended where indicated, particularly for women of childbearing age. Patients should not self-select supplements without dietitian input, as requirements vary.

Monitoring should be more frequent in the first one to two years after surgery. A typical schedule includes blood tests every three to six months in year one to two (covering micronutrients, HbA1c, renal function, lipid profile, and bone profile), moving to annual testing thereafter — lifelong. Patients whose diabetes has gone into remission still require periodic HbA1c monitoring, as relapse is possible.

Contraception and pregnancy: women of childbearing age should avoid pregnancy for at least 12–18 months after surgery, as rapid weight loss and nutritional changes during this period carry risks for mother and baby. Effective contraception should be discussed before surgery. Women planning a pregnancy after this period should seek preconception advice from their GP, diabetes team, and obstetric team.

Follow-up care should include regular appointments with the bariatric MDT, GP, and diabetes team. Psychological support should remain accessible, as body image concerns and emotional eating can re-emerge over time.

Patients are encouraged to contact their GP or bariatric team promptly if they experience persistent vomiting, severe reflux, signs of hypoglycaemia, unexplained fatigue, or any concerns about their recovery. Early intervention consistently leads to better outcomes.

If you experience any suspected side effects from medicines or medical devices, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions